Even the New York Times is talking about the emerging clinical and psychological phenomenon of “food noise” as documented in recent obesity research and GLP-1 drug use. The main reason they’re talking about it is that, for starters, no one really knows for sure why GLP – 1 drugs even work. It’s not even clear about where the effects of the drugs are manifested – whether it’s mostly in the gut, or in the brain, or both. Everyone who is on these drugs is literally a volunteer subject in a massive, uncontrolled “trial” that is teaching scientists and drug developers how it actually works. The latest NYT article discusses the aspect of “food noise.”
What is “Food Noise?”
-
Definition: “Food noise” refers to relentless, intrusive thoughts about food, including internal dialogues regarding what to eat, when to eat, and how to resist cravings.
-
Historical Context: Prior to the widespread use of GLP-1 medications (Ozempic, Wegovy, Mounjaro, Zepbound), this internal buzz was largely ignored by the scientific community.
-
Initial Research Focus: Obesity researchers originally prioritized clinical metrics such as dosage efficacy, weight loss percentages, and improvements in comorbidities like diabetes and sleep apnea.
The Impact of Untested GLP-1 Drugs
-
The Silence Effect: Patients reporting their experiences with GLP-1s highlighted a sudden cessation of the “inner buzz,” an effect that was not a primary target during initial drug development.
-
User Perspective: Many individuals struggling with obesity assumed food noise was a universal experience until medication silenced it, revealing a distinct physiological or psychological driver of their eating habits.
-
The “Internal Auctioneer”: Patients describe the noise as persistent voices that urge the consumption of high-calorie foods (e.g., cake) while dismissing healthier options (e.g., salad).
Scientific Implications
-
Etiology of Obesity: The ability of these drugs to switch off food noise suggests that obesity may be driven by specific neurological signals that compel overeating.
-
Future Research: Scientists are now pivoting to identify the exact biological source of this “inner buzz.” Understanding why it exists and how it is suppressed could lead to a fundamental shift in how obesity is treated and understood.
Bottom Line
No one knows: Since none of these drugs have undergone proper testing, the drug companies and the customers (a.k.a. volunteer test subjects) are conducting the second-largest observational study in the history of drugs (the first being the COVID mRNA gene therapy biologics). It’s the dream situation for the drug companies because their volunteer test subjects are paying them tons of money to be in their study, just like the COVID jab recipients did (although mostly paid by governments). We all know how miserably the COVID jab experiment went, so let’s hope this GLP-1 experiment goes better. I’m not expecting it to, though…
Reference:
Latest Posts
